Novo

Andel Adds Novo's Wegovy Pill and Wegovy HD to Employer Marketplace

Image
Andel Adds Novo's Wegovy Pill and Wegovy HD to Employer Marketplace

NEW YORK – October 29, 2026 -- Andel, a direct-to-employer medication marketplace, has agreed a collaboration with Novo to offer Wegovy, including the once-daily Wegovy pill and Wegovy HD, to its employer network. Both products launched earlier in 2026.

Employers set their own contribution toward obesity treatment

Under the model, employers decide how much to contribute toward each employee's treatment. This lowers out-of-pocket costs for staff while employers keep control of spending. Andel manages the process from prescription verification to delivery through its app.

Andel pitches the offering at employers facing rising medication expenses and sells it as a route outside traditional pharmacy benefits. Large companies, small businesses and startups can all choose a contribution level that fits their budgets. Employees receive manufacturer-direct pricing across Andel's medication platform.

Veeva DQS Cleans Data for 1M+ Trial Subjects, Cuts Manual Work

Image
Veeva DQS Cleans Data for 1M+ Trial Subjects, Cuts Manual Work

Barcelona – October 06, 2026 -- Veeva Systems (NYSE: VEEV) said its Data Quality System (DQS) has aggregated and cleaned data for more than 1 million subjects across over 1,000 clinical studies, automating over 500,000 queries and eliminating thousands of hours of manual data reconciliation for sites and sponsors.

Veeva DQS automates over 500,000 queries to speed analysis-ready data delivery

The platform classifies and visualizes critical trial data while orchestrating risk-based actions across the clinical ecosystem, removing manual reconciliation steps that have historically slowed data lock and submission timelines.

Novo cites rising trial data volume as key driver for automated data management

Ibrahim Kamstrup-Akkaoui, vice president at Novo, said managing data from a growing number of clinical trials is a priority, and that Veeva DQS helps the company manage, format, clean, and prepare data for submission more efficiently.

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

Image
Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.